ATE352319T1 - Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor - Google Patents

Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Info

Publication number
ATE352319T1
ATE352319T1 AT02787572T AT02787572T ATE352319T1 AT E352319 T1 ATE352319 T1 AT E352319T1 AT 02787572 T AT02787572 T AT 02787572T AT 02787572 T AT02787572 T AT 02787572T AT E352319 T1 ATE352319 T1 AT E352319T1
Authority
AT
Austria
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
AT02787572T
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE352319T1 publication Critical patent/ATE352319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02787572T 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor ATE352319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17

Publications (1)

Publication Number Publication Date
ATE352319T1 true ATE352319T1 (de) 2007-02-15

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787572T ATE352319T1 (de) 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Country Status (22)

Country Link
US (3) US7402603B2 (de)
EP (1) EP1443967B1 (de)
JP (1) JP4413614B2 (de)
KR (1) KR100937064B1 (de)
CN (1) CN100457183C (de)
AT (1) ATE352319T1 (de)
AU (1) AU2002351844B2 (de)
BR (1) BR0213932A (de)
CA (1) CA2461373A1 (de)
CY (1) CY1106508T1 (de)
DE (1) DE60217895T2 (de)
DK (1) DK1443967T3 (de)
ES (1) ES2280597T3 (de)
HU (1) HUP0402370A3 (de)
IL (2) IL160970A0 (de)
MX (1) MXPA04004312A (de)
NO (1) NO20042148L (de)
NZ (1) NZ544689A (de)
PL (1) PL205853B1 (de)
PT (1) PT1443967E (de)
RU (1) RU2311200C2 (de)
WO (1) WO2003039599A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2005272389B2 (en) * 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008023438A1 (en) 2006-08-25 2008-02-28 Asahi Glass Co., Ltd. Process for producing 1,2-dialkoxy-3-fluorobenzene
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20080032188A (ko) * 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
CA2653657C (en) 2006-06-12 2015-10-27 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
EP2032532B8 (de) 2006-06-12 2015-07-01 Novartis AG Verfahren zur Herstellung von Salzen des N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamids
KR20140142335A (ko) * 2006-06-12 2014-12-11 노파르티스 아게 Ｎ-히드록시-3-〔4-〔〔〔2-(2-메틸-1ｈ-인돌-3-일)에틸〕아미노〕메틸〕페닐〕-2ｅ-2-프로펜아미드의 동질이상체
US20090281159A1 (en) * 2006-06-28 2009-11-12 Novartis Ag Use of hdac inhibitors for the treatment of lymphomas
US7998957B2 (en) 2007-02-06 2011-08-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
US20100069458A1 (en) * 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
ES2628748T3 (es) 2007-10-01 2017-08-03 Lixte Biotechnology, Inc. Inhibidores de la HDAC
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
JP6118965B2 (ja) * 2012-04-16 2017-04-26 トーアエイヨー株式会社 ２環性化合物
AU2014251087B2 (en) 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EA201792028A1 (ru) 2015-03-13 2018-04-30 Форма Терапьютикс, Инк. Альфа-цинамидные соединения и композиции как ингибиторы hdac8
NZ754522A (en) 2016-12-08 2025-11-28 Lixte Biotechnology Inc Oxabicycloheptanes for modulation of immune response
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
HUP0402370A2 (hu) 2005-02-28
EP1443967A1 (de) 2004-08-11
RU2004117170A (ru) 2005-04-20
DE60217895D1 (en) 2007-03-15
IL160970A0 (en) 2004-08-31
WO2003039599A1 (en) 2003-05-15
PT1443967E (pt) 2007-04-30
DK1443967T3 (da) 2007-04-16
US7402603B2 (en) 2008-07-22
NO20042148L (no) 2004-08-04
MXPA04004312A (es) 2005-05-16
US20080227845A1 (en) 2008-09-18
KR100937064B1 (ko) 2010-01-15
BR0213932A (pt) 2004-08-31
RU2311200C2 (ru) 2007-11-27
CA2461373A1 (en) 2003-05-15
HUP0402370A3 (en) 2008-04-28
PL368539A1 (en) 2005-04-04
KR20050043744A (ko) 2005-05-11
CY1106508T1 (el) 2012-01-25
IL160970A (en) 2010-06-30
JP4413614B2 (ja) 2010-02-10
DE60217895T2 (de) 2007-07-05
US20090192211A1 (en) 2009-07-30
JP2005510517A (ja) 2005-04-21
EP1443967B1 (de) 2007-01-24
US20050032899A1 (en) 2005-02-10
PL205853B1 (pl) 2010-06-30
ES2280597T3 (es) 2007-09-16
CN100457183C (zh) 2009-02-04
NZ544689A (en) 2007-08-31
CN1578674A (zh) 2005-02-09
AU2002351844B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE352319T1 (de) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BR9914044A (pt) ésteres tetrahidropirido
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
DE50310516D1 (de) Fredericamycin-derivate
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
JO2434B1 (en) New retinoids to treat emphysema
ATE438618T1 (de) Inhibitoren von humanem adam-10
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ATE345790T1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
WO2007024574A3 (en) Topical formulations of histone deacetylase inhibitors and methods of using the same
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
ATE453614T1 (de) Sphingolipiden
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE602004008247D1 (de) Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält
SI1594456T1 (sl) Uporaba zmesi, ki vsebuje oksid vitamina k1 ali njegov derivat, pri zdravljenju in/ali preprečevanju dermatoloških lezij pri sesalcih
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona
BRPI0411360A (pt) antranilamidapiridonas inibidores de vegfr-2 e vegfr-3

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443967

Country of ref document: EP